Diplomat Pharmacy Inc (NYSE:DPLO) shares gapped down before the market opened on Monday . The stock had previously closed at $24.60, but opened at $25.19. Diplomat Pharmacy shares last traded at $24.41, with a volume of 276748 shares.
A number of brokerages have recently issued reports on DPLO. Deutsche Bank lowered shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating and boosted their price target for the stock from $22.00 to $29.00 in a research note on Friday. Credit Suisse Group upgraded shares of Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 price target on the stock in a research note on Thursday, January 25th. Mizuho set a $25.00 price target on shares of Diplomat Pharmacy and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Needham & Company LLC boosted their price target on shares of Diplomat Pharmacy from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, January 8th. Finally, Zacks Investment Research upgraded shares of Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 price target on the stock in a research note on Tuesday, October 10th. Seven analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Diplomat Pharmacy has a consensus rating of “Hold” and an average price target of $22.85.
The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82. The stock has a market capitalization of $1,734.92, a P/E ratio of 248.50, a PEG ratio of 3.82 and a beta of 1.06.
A number of hedge funds have recently added to or reduced their stakes in DPLO. PNC Financial Services Group Inc. lifted its holdings in shares of Diplomat Pharmacy by 46.7% in the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after purchasing an additional 2,794 shares in the last quarter. First Allied Advisory Services Inc. purchased a new stake in shares of Diplomat Pharmacy in the second quarter valued at about $183,000. SG Americas Securities LLC purchased a new stake in shares of Diplomat Pharmacy in the third quarter valued at about $191,000. Piedmont Investment Advisors LLC purchased a new stake in shares of Diplomat Pharmacy in the third quarter valued at about $216,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Diplomat Pharmacy in the fourth quarter valued at about $244,000. 69.87% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Diplomat Pharmacy (DPLO) Shares Gap Down to $25.19” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2018/02/05/diplomat-pharmacy-dplo-shares-gap-down-to-25-19.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.